Supporting primary care to optimise lipid management pathways


Together with our partners in health and care across Devon, Somerset, Cornwall and the Isles of Scilly, we are working to optimise lipid management pathways to effectively treat patients with the right lipid-lowering medication at the right time.

As part of a consistent, national approach, we are using an awaited NICE (National Institute for Health and Care Excellence) approved pathway with the aim of reducing health inequalities, the risk and impact of long-term conditions such as heart attack and ischemic stroke, and hospital admissions and re-admissions. The pathway will also provide more treatment options to high-risk patients who remain at risk despite maximum tolerated statin therapy.


The current lipid management pathway for primary and secondary prevention of cardiovascular disease includes the following medicines:

  • High-intensity statins:
  • Atorvastatin (20mg to 80mg)
  • Rosuvastatin (10mg to 40mg)
  • Ezetimibe
  • PCSK9 inhibitors (PCSK9i):
  • Alirocumab
  • Evolocumab

High-intensity statins and ezetimibe are available as generic medicines and are prescribed in primary and secondary care. PCSK9i are prescribed in secondary care.

Recently, updates to lipid pathways have seen the introduction of new medications to lower lipid levels in patients. These medications, Inclisiran and Bempadoic Acid, have been approved by NICE and will give clinicians an additional option to treat cholesterol levels down to target levels for patients with, or at high risk of, cardiovascular disease (CVD).

As part of a national drive, NHS England has enlisted Academic Health Science Networks (AHSNs) across the country to support primary care in understanding where these new drugs are placed for patients with hypercholesterolaemia and those who have had previous cardiovascular events such as acute coronary syndrome, ischemic stroke and peripheral arterial disease.


We are supporting primary care teams in South West England to initiate the timely adoption, prescribing and funding of Inclisiran within their primary care setting.

We are engaging with local Integrated Care Systems (ICSs) and Primary Care Networks to lead local decision-making, underpinned by local population data, to enable a targeted Population Health Management approach. Learn more about the partnership between the NHS and AHSNs to introduce Inclisiran.


We are continually gathering the latest tools and resources to support you to optimise cholesterol management. Here you’ll find information on Inclisiran and resources to facilitate its implementation, as well as more information on lipid management.

VIDEO: Inclisiran explained, an innovative new treatment for people at risk of cardiovascular disease

Dr Phil Jennings, Chief Officer of the Innovation Agency and AHSN Network Lead for the Rapid Uptake Products, explains the new treatment inclisiran in this video for GPs and healthcare professionals*.

*Created to inform healthcare professionals only, to support them to roll-out the treatment.